Testing IBI3032 in healthy volunteers
This study tests a new drug called IBI3032 in healthy volunteers to see how safe it is and how the body processes it. If you are in good health, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be in good general health.
- You cannot have any known allergies to IBI3032 or similar drugs like GLP-1 analogs.
- Your heart tracing (ECG) must be normal.
- You cannot have a history of serious medical conditions like heart, lung, liver, kidney, or blood problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how safe and tolerable different doses of the study drug BI 3814916 are in healthy adults. It helps find the right dose for future studies.
This study tests how a new medicine (BI 3034701) moves through the body in healthy men who have normal weight or are overweight. It helps find the right dose and understand how the medicine works.
This study tests how a new medicine, BI 3000202, is absorbed into the blood. It includes people with different levels of liver function (normal, mild, moderate, or severe) to see if liver problems affect how the medicine works.
This study tests a new medicine (BI 3776528) in healthy men to see how well different doses are tolerated. It helps researchers find the safest dose before testing in people with a condition.
This is an early-stage safety study of a new drug called IBI3035 in healthy adult volunteers. Researchers want to understand how the drug is absorbed and processed by the body, and whether it causes any side effects.
This trial tests a new medication called IBI3032 in healthy people and those with overweight or obesity. It aims to see if the drug is safe and how the body processes it.
Hear when a new Healthy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.